PHATHOM PHARMACEUTICALS, INC. Stock Split Ratio
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Stock Split Ratio of 216.80% as of 2019-10-11, per its 10-Q filed 2020-11-10.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2020-11-10
- PHATHOM PHARMACEUTICALS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2018 was 155911.83%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|
| 2019-10-11 | 216.80% 10-Q · filed 2020-11-10 | |
| 2018-12-31 | 155911.83% 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |